Drug
Povorcitinib clinical trials
Also written INCB054707.
Includes 1 study of Povorcitinib phosphate.
- studies test it
- 24
- open now
- 3
- in phase 3
- 9
- first study started
- 2018
Keep track of what changes. Save the povorcitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
24 studies that test it; most in 2023 (6)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 8
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 0
Incyte Corporation (22) · Incyte Biosciences Japan GK (1) · Dermavon Holdings Limited (1)
Often tested with
Tested in the same studies.
Ruxolitinib (1) · Levonorgestrel (1) · Ethinyl Estradiol (1)
Studies
Open first, then newest update. How each study uses povorcitinib is read from its arms, and is right about nine times in ten.
Testing it · 24
- Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibRecruitingPhase 3Incyte CorporationNCT06855498Written as povorcitinib
- Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaRecruitingPhase 2Incyte CorporationNCT07213973Written as Povorcitinib
- A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental VitiligoNot yet recruitingPhase 3Dermavon Holdings LimitedNCT07865312Written as Povorcitinib phosphate
- A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult ParticipantsCompletedPhase 1Incyte CorporationNCT07588139Written as Povorcitinib
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingPhase 3Incyte CorporationNCT06212999Written as Povorcitinib
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)Active, not recruitingPhase 3Incyte CorporationNCT06113445Written as Povorcitinib
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaActive, not recruitingPhase 2Incyte CorporationNCT05851443Written as povorcitinib
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)Active, not recruitingPhase 3Incyte CorporationNCT06516952Written as Povorcitinib
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)Active, not recruitingPhase 3Incyte CorporationNCT06516965Written as Povorcitinib
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)Active, not recruitingPhase 3Incyte CorporationNCT06113471Written as Povorcitinib
- Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous UrticariaCompletedPhase 2Incyte CorporationNCT05936567Written as Povorcitinib
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 3Incyte CorporationNCT05620823Written as Povorcitinib
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedPhase 3Incyte CorporationNCT05620836Written as Povorcitinib
- A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedPhase 2Incyte CorporationNCT03607487Written as INCB054707
- To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedPhase 2Incyte CorporationNCT04476043Written as INCB054707
- A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentCompletedPhase 1Incyte CorporationNCT05624710Written as INCB054707
- A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo NodularisCompletedPhase 2Incyte CorporationNCT05061693Written as INCB054707
- A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy ParticipantsCompletedPhase 1Incyte CorporationNCT06505265Written as Povorcitinib
- A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy ParticipantsCompletedPhase 1Incyte CorporationNCT06441318Written as Povorcitinib
- A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult FemalesCompletedPhase 1Incyte CorporationNCT06380205Written as Povorcitinib
See all 24 studies that test povorcitinib →
Given in every arm · 1 — povorcitinib is usual care beside what is tested
Codes
What other systems call povorcitinib · ClinicalTrials.gg INT017344
- UNII (FDA) N0JWC7RO00POVORCITINIBOne source FDA
- NCI Thesaurus C188603PovorcitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | N0JWC7RO00 | POVORCITINIB | One source FDA |
| NCI Thesaurus | C188603 | Povorcitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.